Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.63 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.63 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.63 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987983 | 0.98 | NR4A2 (0.65) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL28488225 | 0.88 | NR4A1 (0.59) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL2981632 | 0.86 | NR4A1 (0.61) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL4220394 | 0.86 | SRD5A2 (0.54) | NR4A2NR4A1NR4A3SRD5A2TSHR | |
| SCHEMBL9568480 | 0.86 | TSHR (0.57) | NR4A2NR4A1NR4A3TSHRMEN1 | |
| SCHEMBL4231246 | 0.84 | SRD5A2 (0.55) | NR4A2NR4A1NR4A3SRD5A2TSHR | |
| Silver SCHEMBL4220651 | 0.84 | TSHR (0.49) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL21419139 | 0.84 | TSHR (0.51) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL28626541 | 0.83 | SMN1; SMN2 (0.57) | NR4A2NR4A1NR4A3SRD5A2TSHR | |
| SCHEMBL16011563 | 0.83 | NR4A2 (0.66) | NR4A2NR4A1NR4A3SRD5A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189840-B1 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190142815-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | ALTER DOMUS (US) LLC | 2019-05-16 | — | — | US | disclosed |
| US-10231960-B2 | Methylphenidate-prodrugs, processes of making and using the same | KEMPHARM INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3189840-A1 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-2736510-B1 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9453037-B2 | Methylphenidate-prodrugs, processes of making and using the same | KEMPHARM, INC (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2015-09-24 | — | — | US | disclosed |
| US-9079928-B2 | Methylphenidate-oxoacid conjugates, processes of making and using the same | KEMPHARM, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMMAVE THERAPEUTICS SA (CH) | 2014-08-28 | — | — | US | disclosed |
| EP-2736510-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013016668-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| US-7572795-B2 | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090156555-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-18 | — | — | US | disclosed |
| EP-2001886-A2 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007103839-A2 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213300-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156555-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | CDK2, CDK3, CDK1 | NR4A2 2218/4885NR4A1 2433/4885NR4A3 1710/4885 |
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMT, PNMT, SLC6A3 | NR4A2 1998/4885NR4A1 1101/4885NR4A3 1175/4885 |
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | NR4A2 1930/4885NR4A1 1012/4885NR4A3 1196/4885 |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | NR4A2 1930/4885NR4A1 1012/4885NR4A3 1196/4885 |
| US-20070213300-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | CDK2, CDK3, CDK1 | NR4A2 2162/4885NR4A1 2402/4885NR4A3 1704/4885 |
| US-20190142815-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | NR4A2 1930/4885NR4A1 1012/4885NR4A3 1196/4885 |
| US-10231960-B2 | Methylphenidate-prodrugs, processes of making and using the same | COMT, TPMT, PNMT | NR4A2 1930/4885NR4A1 1012/4885NR4A3 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.